SIP
ITCI

Stoneridge Investment Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Stoneridge Investment Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,007
Closed -$751K – 334
2016
Q1 		$751K Buy
+27,007
New +$900K 0.11% 178

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Stoneridge Investment Partners's ITCI Position: Q2 2016 in Review

Stoneridge Investment Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2016, closing a stake of 27,007 shares — an estimated $751K sold.

Stoneridge Investment Partners first reported a position in ITCI in Q1 2016 and held it in 1 quarter. The position peaked at $751K in Q1 2016. 139 funds tracked by Wall St. Rank hold ITCI as of Q2 2016.

  • Stoneridge Investment Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 27,007 Intra-Cellular Therapies Inc. shares in Q2 2016, an estimated $751K.
  • Stoneridge Investment Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 1 quarter.
  • Stoneridge Investment Partners's Intra-Cellular Therapies Inc. position peaked at $751K in Q1 2016.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2016.

Based on Stoneridge Investment Partners's 13F filing for Q2 2016, filed 25 Jul 2016.